background: Smooth muscle cells (SMC) are common components of endometriotic lesions. SMC have been characterized previously in peritoneal, ovarian and deep infiltrating endometriotic lesions and adenomyosis. The aim of this retrospective study was to investigate the extent of differentiation in endometriosis-associated SMC (EMaSMC) in peritoneal endometriotic lesions.
Introduction
Endometriosis is defined as a benign, chronic, estrogen-dependent gynaecologic disease affecting millions of women of reproductive age (Bulun, 2009) . Most of the patients suffer from cycle-dependent symptoms, such as dysmenorrhoea and pelvic pain, whereby 50% of those need long-term treatment with recurrent surgery and/or persistent hormonal treatment (Gao et al., 2006) . Owing to the complex pathogenesis of endometriosis, therapeutic options are currently available for the treatment of symptoms but not for healing (Leyendecker et al., 2009) . In spite of surgical excision of the lesions and adjuvant hormonal treatment, the recurrence rate and persistence of symptoms associated with endometriosis is up to 40% (Catenacci et al., 2009) . As long as the pathogenesis of endometriosis, especially the pathogenesis of pain generation, is not fully understood, the development of specific, successful treatment options will be hindered.
Currently, the histological criteria to define endometriosis are the detection of ectopic endometrial glandular cells with surrounding stromal cells and/or macrophages. In addition, smooth muscle cells (SMC) are frequent components of endometriotic lesions (Khare et al., 1996; Anaf et al., 2000; Leyendecker et al., 2002; Mechsner et al., 2005) . SMC have been detected in peritoneal (Anaf et al., 2000; Mechsner et al., 2005) , ovarian (Fukunaga, 2000; Mechsner et al., 2005) and deep infiltrating (van Kaam et al., 2008) endometriotic lesions, and also in adenomyosis uteri (Mechsner et al., 2010) and in extragenital bowel wall endometriosis (Kazakov et al., 2007; Mechsner et al., 2009b) .
However, to date, the origin of these endometriosis-associated SMC (EMaSMC) is still unclear. There is some evidence that EMaSMC are of metaplastic origin (Anaf et al., 2000; Mechsner et al., 2005; Odagiri et al., 2009) . Furthermore, the biological functionality of EMaSMC has not been clarified.
Peritoneal EMaSMC (pEMaSMC) express oxytocin receptors (OTRs), estrogen receptors (ERs) and progesterone receptors (PRs), which are essential components characterizing uterine myometrial cells (Mechsner et al., 2005) . In contrast, the ability of pEMaSMC to show contractions has been not demonstrated. It seems possible that peritoneal SM contractions could stimulate peritoneal nociceptors leading to the generation of endometriosis-associated pain (Mechsner et al., 2005; Odagiri et al., 2009) .
To characterize EMaSMC in peritoneal endometriotic lesions, we performed immunohistochemical analysis of well-known uterine markers and markers of smooth muscle differentiation which are expressed in human peritoneal endometriotic lesions.
Materials and Methods

Tissue samples
Biopsies were obtained from 60 patients who underwent diagnostic laparoscopy/laparotomy for symptomatic endometriosis (pelvic pain, dysmenorrhoea, dyspareunia, dysuria or dyschezia). The biopsy specimens were obtained by performing a wide excision, without using coagulating diathermy. All women were premenopausal with a mean (+SD) age of 33 + 6.5 years (range: 19 -47). Thirty-eight women had regular menstrual cycles without hormonal treatment, whereas 22 patients were under hormonal treatment. The respective phases of the cycle were defined by correlating the date of the last menstrual period and the date of surgery (secretory phase n ¼ 20, proliferative phase n ¼ 18). The staging of endometriosis was performed according to the revised classification of the American Society of Reproductive Medicine (rASRM; stage I, n ¼ 23; II, n ¼ 19, III, n ¼ 13; IV, n ¼ 5; Medicine, 1997) . Peritoneal endometriotic lesions were classified into black or white fibrotic implants (n ¼ 40) and red lesions (n ¼ 3), and 17 could not be assessed. The lesions were excised from peritoneum of the lateral pelvic wall (n ¼ 4), the bladder (n ¼ 16), pouch of Douglas (n ¼ 11), the fossa ovarica (n ¼ 10), the uterosacral ligament (n ¼ 14) and peritoneum (n ¼ 5).
In addition, peritoneal biopsies, distant from the endometriotic lesion, from patients with endometriosis (n ¼ 60) and peritoneal biopsies of healthy peritoneum from patients without endometriosis (control tissue; n ¼ 10) were used. All peritoneal biopsies had subperitoneal fat at the lower border.
All excised lesions were fixed immediately in 4% buffered formalin (Hedinger, Stuttgart, Germany) for 12 h and then embedded in paraffin. Serial sections (1 mm thick) were cut and stained with haematoxylin and eosin (H&E), or immunostained.
All patients gave their written informed consent and the study was approved by the Institutional Review Board.
Immunohistochemistry
Negative control sections were processed by omitting the primary antibody and by competition test with a specific blocking peptide (Santa Cruz Biotechnology Inc., CA, USA). Endometrium was used as positive control for CD10, ER and PR staining; myometrium from a pregnant uterus was used for the OTR and vasopressin receptor (VPR) staining; and leiomyoma tissue was the control for the staining of smooth muscle actin (smActin), caldesmon, desmin and smooth muscle myosin heavy chain (SM-MHC). The quality of the staining was supervised and confirmed by our pathologist and also confirmed by the controls.
CD10 staining
Immunohistochemical analysis was performed as described previously (Mechsner et al., 2009b) . Briefly, the sections were incubated for 1 h at room temperature with a monoclonal mouse anti-CD10 antibody (a specific marker for endometrial stromal cells; McCluggage et al., 2001 ; dilution 1:50, Sigma, Germany). After rinsing with tris-buffered saline (TBS), the Labelled-Strept-Avidin-Biotin-Kit (LSAB; Dako, Hamburg, Germany) and Fuchsin-substrate (Dako, Hamburg, Germany) were used to visualize the specific immunoreactive CD10 staining.
smActin, caldesmon, desmin and SM-MHC staining
The sections were processed as described above and then incubated for 1 h at room temperature with a monoclonal mouse anti-smActin [specific marker for SMC and myofibroblast (Hasegawa et al., 2003) ], mouse anti-caldesmon [marker for differentiated SMC (Hasegawa et al., 2003) ], mouse anti-desmin [marker for differentiated SMC (Hasegawa et al., 2003) ] or a mouse anti-SM-MHC [a marker molecule restricted for the SMC (Manabe and Owens, 2001 )] antibody (dilution 1:50, Dako, Hamburg, Germany). After rinsing with TBS, the sections were treated as described above.
ER and PR staining
Immunohistochemistry analysis was performed as described above. Briefly, the sections were incubated with a monoclonal mouse anti-ER antibody (clone 1D5, dilution 1:35, DakoCytomation, Denmark) or with a monoclonal mouse anti-PR (clone 1A6, 1:50 DakoCytomation, Denmark) for 1 h at room temperature. The secondary biotinylated rabbit anti-mouse immunoglobulin (Ig) G antibody (dilution 1:400, Dianova, Germany) was applied for 40 min. Streptavidin (dilution 1:400, Roche, Germany) was applied for 40 min. Fuchsin-substrate (Dako, Hamburg, Germany) was used to visualize the specific immunoreactive staining.
OTR and VPR staining
The sections were incubated for 1 h at room temperature with a polyclonal goat anti-OTR antibody (dilution 1:50, Santa Cruz Biotechnology Inc.) or polyclonal goat ant-VPR antibody (dilution 1:100, Santa Cruz Biotechnology Inc.). The secondary biotinylated rabbit anti-goat IgG antibody (dilution 1:400, Dianova, Germany) was applied for 40 min. After rinsing with TBS, the sections were treated as described above.
Evaluation of the immunohistochemistry
The staining was evaluated using a Carl Zeiss (Gö ttingen, Germany) Axiophot microscope. Pictures were taken with different magnifications (×25, ×40 or ×100).
The number of SMC in peritoneal endometriotic lesions was estimated in different locations according to their relationship to the endometriotic lesions [intrastromal SMC (ISMC), surrounding SMC (SSMC) and peripheral SMC (PSMC)] and in control tissue (i.e. healthy peritoneum from women without endometriosis) by defining the percentage of the total area studied, occupied by SMC, unassociated with blood vessels, as described (Mechsner et al., 2005) . Briefly, the relative area (percentage, mean + SD) occupied by SMC was evaluated in at least 10 nonoverlapping randomly selected high power fields (×400) on each slide for endometriotic lesions and in each biopsy for healthy peritoneum with the same pelvic location. Sections were evaluated by two independent observers who were blinded to the nature of the samples.
The OTR, ER and PR staining was scored as described previously (Mechsner et al., 2005) .
Statistical analysis
The data were evaluated using the non-parametric test (Mann-Whitney test, to test two independent groups), the non-parametric one-way analysis of variance (ANOVA) (Kruskal -Wallis test, to test three or more groups) or the two-way ANOVA (to test two independent variables). The Dunn's multiple comparison and the Bonferroni post-test were used as post hoc tests. Statistical significance was defined as P , 0.05. Statistical analysis was performed using Prism 4 for Windows (GraphPad Software, 2003, San Diego, CA, USA) .
Results
In all samples studied, H&E staining did confirm the presence of endometriotic glands with epithelial cells and surrounding stromal cells. 
Endometriosis-associated smooth muscle cells
Detection of SMC in peritoneal endometriotic lesions
Using anti-smActin antibody, SMC could be detected in all peritoneal specimens from women with endometriosis, while in healthy peritoneum from women without endometriosis (control group), only 30% of the specimens did contain SMC (Mann-Whitney test; P , 0.0001; Fig. 1a-c) . CD10 staining was strong in the stromal region of peritoneal endometriotic lesions (Fig. 1d) . The tissue surrounding endometriotic lesions is smActin positive but not in healthy peritoneum from the control group (Fig. 1b and c) . The total number of smActin-positive cells was higher in the peritoneum of women with endometriosis (38%) compared with healthy peritoneum of patients without endometriosis (control group; 6%; Mann-Whitney test; P , 0.0001; Fig 1e) .
Therefore, we defined those SMC in peritoneal specimens of patients with endometriosis as EMaSMC.
Localization of the EMaSMC
EMaSMC spread could be differentiated according to their relationship with the endometriotic lesion. ISMC, surrounding SSMC and PSMC could be distinguished (Fig 2a) . These forms of SMC were present in all lesions investigated, and 25% of the stromal region, 65% of the surrounding tissue and 31% of the peripheral tissue were positive for smActin (Fig. 2b) . The amount of SMC in the tissue surrounding the lesion is increased when compared with stromal or peripheral tissue (Kruskal -Wallis test; P , 0.0001; Fig 2c) .
Further, the localization of EMaSMC in different macro-anatomical regions of the peritoneum from women with endometriosis was analysed. There were no significant differences in the amount of the EMaSMC between the anatomical regions (ISMC, SSMC or PSMC; two-way ANOVA; P . 0.05; Fig. 2d ).
There was no association between the SM-amount in the peritoneal endometriotic lesion and the current endocrine treatment or phase of the menstrual cycle (Table I ). In addition, there was no difference in the occurrence of EMaSMC between red active and black or white fibrotic inactive endometriotic lesions (P . 0.05). The SM-content was lower in peritoneal specimens of patients with recurrent endometriosis than in patients with primary diagnosed endometriosis (P , 0.05; Table I ). There was also no association between EMaSMC and the rASRM stage (P . 0.05; Table II) .
SM-differentiation
EMaSMC (ISMC, SSMC and PSMC) were analysed to determine the SM-differentiation by using the SM-differentiation markers, desmin and caldesmon. Desmin and caldesmon were decreased in all EMaSMC when compared with the total level of smActin-positive cells (P , 0.001 for ISMC and SSMC and P , 0.01 for PSMC; Fig. 3a) . The peritoneal SMC from healthy women expressed all markers equally (not shown). The differentiation grade of ISMC was 12 -15% of the SMC and that of the smActin-positive cells was 36 -44% of the SSMC, while PSMC differentiated up to 77-80% of the SMC (Fig. 3b) . The number of differentiated cells was increased in the PSMC when compared with the ISMC or SSMC (two-way ANOVA; P , 0.001; Fig 3b) .
Detection of SM-MHC, OTR, VPR and ER/PR in EMaSMC
SM-MHC, OTR and VPR immunostaining was studied in ISMC, SSMC and PSMC. Minimal to moderate staining of the SM-MHC was detected in 100% of the ISMC, SSMC and PSMC in investigated specimens (Fig. 4a) . Forty-seven per cent of the ISMC smActin cells were positive for SM-MHC together with 62% of the SSMC and 88% of the PSMC (Fig. 4b) . The percentage of SM-MHC-positive cells was higher in PSMC compared with the ISMC or SSMC (two-way ANOVA; P , 0.001 and P , 0.01, respectively; Fig. 4b ).
Weak to moderate OTR staining was found in 97% of the SSMC and PSMC, while OTR was only expressed in 61% of the endometriotic tissue in the ISMC (P , 0.001). Only 40% of the smActin-positive cells in the ISMC and SSMC expressed the OTR, while 83% of the SMC in PSMC were stained for OTR ( Fig. 4a and b) .
In addition, the functionality of the EMaSMC was also analysed with the VPR. The VPR was weakly stained in ISMC (10%), but stained in 90% of the SSMC and PSMC (P , 0.0001). Eight per cent of smActinpositive cells positive for the VPR could be determined in the ISMC, 28% in the SSMC and 62% in the PSMC (Fig. 4a and b) .
Additionally, moderate staining for ER and PR was detected in 98% of EMaSMC in the peritoneal endometriotic lesion (Fig. 5) . Eighty-eight per cent of epithelial cells and 66% of stromal cells showed the presence of ER, while 95% of epithelial cells and 82% of stromal cells stained for PR (Fig. 5a ). The staining for both receptors was higher in the epithelial cells compared with stromal cells (two-way ANOVA; ER: P , 0.001 and PR: P , 0.01, Fig. 5a ). Fifty-three per cent of the smActin-positive cells in the SSMC expressed the ER and 73% the PR, while 46% of the SMC expressed the ER and 67% the PR in PSMC (two-way ANOVA; Fig. 5b and c) .
Discussion
The present study provides first evidence for a possible metaplastic origin of pEMaSMC with various grades of differentiation, and expression of uterine marker molecules (OTR, VPR and ER/PR) in fully developed SMC.
Owing to the low visibility of SMC in H&E staining, the SMC could not be distinguished easily from the fibroadipocyte connective tissue in peritoneum. However, De Snoo already described in his morphological histological studies of 1942 that EMaSMC are frequent components in endometriosis (De Snoo, 1942) . Using modern techniques of immunohistochemistry, SMC were detectable in all types of endometriotic lesions (Anaf et al., 2000; Fukunaga, 2000; Mechsner et al., 2005; Kazakov et al., 2007; van Kaam et al., 2008; Mechsner et al., 2009b Mechsner et al., , 2010 . The origin and functionality of SMA cells in endometriosis is still not completely known.
In the first step of our analysis, we calculated the SM-amount in peritoneal endometriotic specimens in comparison with healthy unaffected peritoneum and we could demonstrate that the SM-amount in peritoneal endometriotic lesions was significantly higher than in healthy peritoneum. In all endometriotic specimens SMC have been detected and the SM-content was up to 40%. The SMC were present independent of the anatomical localization of the peritoneal biopsy, the stage of disease, the phase of the cycle or hormonal treatment. Only in cases of recurrent disease was the SM-amount lower than in first-diagnosed cases. SMC close to the endometriotic lesion (ISMC/SSMC) seem to be immature, whereby the PSMC are fully differentiated. These findings could be demonstrated by immunohistological staining of the SM-differentiation markers, caldesmon and desmin. The staining for both OTR and VPR was also significantly higher in the mature than in immature SMC.
The question now is: where do these SMC come from? Are they developed by a remodelling pathway of current peritoneal fibroblasts, by metaplastic changes of endometriotic stromal cells or by reactivation of coelomic epithelial cells?
The common part of all these theories is the differentiation of fibroblasts to myofibroblasts, which leads to the expression of smActin in differentiated SMC (Desmouliere et al., 1993) . The basic mechanism which induces this process is still unclear. The close morphological connection of immature SMC formations with stromal cells of endometriotic lesions could suggest smooth muscle metaplasia (SMM) out of stromal cells. The expression of the OTR/VPR, markers for uterine SMC (Fuchs et al., 1985 (Fuchs et al., , 1998 , indicates that these cells may originate from a metaplastic transformation of uterine stromal cells outside the uterus. In addition, the reported expression of CD10, a marker for endometrial stromal cells, suggests the metaplastic origin of the components in endometriotic lesions from uterine cells (Sumathi and McCluggage, 2002) .
However, whether these EMaSMC cells derive from basal stem cells or reactivated coloemic epithelial cells is still unclear (Signorile et al., 2009) . There are several arguments encouraging both hypotheses. De Snoo discussed the origin of these EMaSMC as reactivation of residua out of the paramesonephric ducts, like the embryological development of the uterus and Fallopian tubes out of omnipotent cells, and described ectopic endometriotic cells as 'miniature uteri' (De Snoo, 1942) . The observation of differentiated and undifferentiated SMC in primary umbilical endometriotic lesions affirmed the hypothesis that epithelial and stromal cells might develop from persistent coelomic epithelial cells by metaplasia (Mechsner et al., 2009b) . Coelomic epithelial cells arise during the embryonic period in the umbilicus and regress after closing the physiological omphalocele at 12 weeks of gestation. However, persistent umbilical hernia after birth could be one factor related to the persistence of such multipotent coelomic epithelial cells (Meyer, 1930) : in addition, the recent analysis of dislocated primitive endometrial tissue outside the uterine cavity during organogenesis supported this hypothesis (Signorile et al., 2009 ).
On the other hand, SMC were observed in secondary, abdominal wall endometriosis, which have developed in scars following the transplantation of active endometrial tissue during surgery, for example during Caesarean section (Kazakov et al., 2007) . In primary and secondary abdominal wall endometriosis, SMC were localized between endometriotic stromal cells, suggesting that, in both cases, SMC originate from endometriotic cells as a result of epithelial -mesenchymal transition of the cells (Kazakov et al., 2007; Hayashida et al., 2010) .
In this respect, physiological SMM in the junctional zone of the uterus has previously been reported (Konishi et al., 1984; Fujii et al., 1989) . It seems to be possible that cells from the basal endometrial layer, with stem cell characteristics, were catapulted out of the junctional zone due to pathological contractility patterns (Leyendecker et al., 2009 ). These stem cell-like fragments may be able to adhere Endometriosis-associated smooth muscle cells to the peritoneum and differentiate into a 'miniature-uterus' by a metaplastic process (De Snoo, 1942; Leyendecker et al., 2002; Mechsner et al., 2005; Leyendecker et al., 2009 ). The recent characterization of stem cells in the endometrial basal layer encourages this discussion (Gotte et al., Epub2010) . Furthermore, the expression and release of transforming growth factor (TGF) b1 in endometrial epithelial cells leads to decidualization of endometrial stromal cells, followed by the expression of smActin (Kim et al., 2005) .
Contrary to the hypothesis of SMM, the development of SMC as a reaction of the surrounding tissue has to be discussed. In an ovarian endometriotic cyst, SMC were identified (Fukunaga, 2000; Mechsner et al., 2005) . In contrast to peritoneal and abdominal wall endometriosis, these SMC were arranged in a circular manner around the ovarian endometriotic cyst, with no mixing of stromal cells and SMC (Fukunaga, 2000) . The observation of SMC in the ovary is not just an endometriosis-associated phenomenon as the occurrence of SSMC could be detected in other benign masses (Doss et al., 1999) , suggesting that the development of SMC is a reaction of the ovarian stromal cells. SMC are also well described in deep infiltrating endometriosis (DIE) (Nisolle and Donnez, 1997; Anaf et al., 2000; Itoga et al., 2003) . Markers of SM differentiation, such as vimentin, desmin, a-smActin and SM-MHC, have been studied in DIE (van Kaam et al., 2008) . In agreement with our data, different levels of SMC maturation in the endometriosis-associated fibro-connective tissue were found (van Kaam et al., 2008) . Furthermore, TGF-b expression in endometriotic epithelial cells was demonstrated, suggesting the influence of TGF-b-positive cells on the induction of SMM. The transplantation of human endometrial cells in a mouse model induced SMM, however, these SMC seem to result from the reaction of the fibroconnective tissue of the mouse (van Kaam et al., 2008) , suggesting an environment similar to wound healing (van Kaam et al., 2008) . In addition, Hull et al. (2008) studied the endometrial-peritoneal interaction during endometriotic lesion establishment in a nude mouse model: they demonstrated a host reaction against human tissue, with a detection of murine macrophages and smooth muscle actinpositive cells within the human ectopic endometrial lesion. Owing to the fact that endometrial tissue from the functional layer (collected using pipelle biopsy) was transplanted into the peritoneal cavity of the nude mice, a failure of smooth muscle actin-positive cells seems to be plausible. This model demonstrates the host reaction with the ability of myofibroblastic transdifferentiation. In fact, peritoneal myofibroblastic transdifferentiation/conversion of mesothelial cells in women without endometriosis is well documented, especially in patients with peritoneal fibrosis (Yang et al., 2003; De Vriese et al., 2006; Witkowicz, 2008) , and seems to be another important mechanism in the development of endometriotic lesions. Khare et al. investigated the myofibroblast proliferation and changes in collagen deposition in ovarian and pelvic wall-infiltrating endometriosis and demonstrated that in ovarian endometriosis the endometriotic lesions are lying on the inside of the chocolate cyst and are not freely intermixed with native ovarian collagen, whereas pelvic wall-infiltrating endometriosis showed endometriotic lesions mixing freely with the native pelvic wall collagen (Khare et al., 1996) . However, both kinds of SMM are possible and do not exclude each other, and further investigations are needed to clarify the origin of these EMaSMC.
Another point of interest in this study was the possible contractility of EMaSMC. We previously reported that EMaSMC express OTR and ER/ PR (Mechsner et al., 2005) , which may be involved in endometriosis-associated pain induction. It seems possible that the chaotic/irregular contractions of peritoneal SMC mediated by OTR could lead to peritoneal irritations and to an activation of nociceptors. Furthermore, contractions may lead to local tissue injury with induction of repair mechanisms associated with P450 aromatase overexpression and the consequences on local estrogen synthesis (Leyendecker et al., 2009) . Recently, the OT-dependent uterine contractions of the junctional zone in the non-pregnant uterus were described (Kunz et al., 1998) . Our results demonstrate a comparable grade of muscle level in peritoneal endometriotic lesions independent of the activity of the lesions (red active lesions produce all kinds of bioreactive pro-inflammatory substances and estrogen, whereas black or white inactive lesions lack this excretion) and rASRM classification. The SM level is low in healthy peritoneum (Mechsner et al., 2005) and significantly increased in areas of peritoneal endometriotic lesions. These findings could explain the stage-independent presence of endometriosis-associated symptoms (Fedele et al., 1990; Vercellini et al., 1996) .
OT seems to promote the release of prostaglandin (PG)F 2a from endometrial cells (Wilson et al., 1988; Burns et al., 2001) , and the release of PGF 2a and endothelin mediates myometrial contractility in a paracrine and/or autocrine fashion (Bacon et al., 1995) . Therefore, we believe that OT could mediate a similar effect in epithelial cells of peritoneal endometriosis and the adjacent SMC. Here, a further uterotonic marker, VPR, was detected in pEMaSMC. In agreement with Odagiri et al. (2009) , these data showed a biological explanation for SM contraction, which might be an important mechanism in the generation of endometriosis-related pelvic pain. Furthermore, the expression of myosin heavy-chain-a marker molecule restricted to the SMC (Manabe and Owens, 2001 )-suggests the possibility of contractile activity in EMaSMC.
In addition to the other known pain mechanisms of endometriotic implants, such as the release of pain mediators or nerve growth factor and PGs produced by endometriotic lesions (Vernon et al., 1986; Muzii et al., 1997; Anaf et al., 2002) , and the close topographical relationship to nerve fibres (Anaf et al., 2002; Mechsner et al., 2009a) with perineuronal invasion, EmaSMC seems to be a further factor in the complex process of pain generation.
In summary, this is the first study which suggests metaplastic changes in pEMaSMC in different grades of SM-differentiation, with the possibility of contraction, although a dynamic in vitro or in vivo study is required to fully demonstrate metaplasia of cells. Our data suggest that the specific inhibition of OTR might be a promising additional new approach for the treatment of pain associated with endometriosis.
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